April 26, 2017 7:12 AM EDT Initial Data from Global Phase 2 Program Expected Mid-2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has initiated dosing in the Companys global Phase 2 clinical program evaluating RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company
- Welcome to PNH Support!
News
1st October 2018
CO-ORDINATED CARE OF RARE DISEASES (CONCORD)
10th August 2018
Article on Treating AA and PNH at the same time.
12th July 2018
Results from Phase 1b Studies for C3 Inhibitor
12th July 2018
Phase 1 Trial starts for Achillion’s Oral Therapy
9th February 2018
Good results for the Phase 2 Coversin drug trial (daily injection)
2nd March 2017
APPG Report on UK Strategy for Rare Diseases in England
The All Party Parliamentary Group (APPG) on Rare, Genetic and Undiagnosed Conditions published a report yesterday looking at the implementation of the UK Strategy for Rare Diseases in England. The APPG has found that the Strategy is not being effectively implemented in England. England is the only country in the United Kingdom where an implementation
1st March 2017
Eculizumab: another breakthrough (Journal Article)
In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement. Read More